{"@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [{"@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.patentleaderboard.com/"}, {"@type": "ListItem", "position": 2, "name": "Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer", "item": "https://www.patentleaderboard.com/patent/10695426"}]}
Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer

Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer

US Patent 10695426 · Granted Jun 30, 2020

Estimated economic value: $597,435,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Regulated transcription of targeted genes and other biological events2005
NF-AT polypeptides and polynucleotides and screening methods for immunosuppressi2005
NF-AT polypeptides and polynucleotides2002
NF-AT polypeptides and polynucleotides and screening methods for immunosuppressi2002
Regulated apoptosis2001
NF-AT polypeptides and polynucleotides2001
NF-AT polypeptides and polynucleotides2001
NF-AT polypeptides and polynucleotides2001
NF-AT polypeptides and polynucleotides2000
Regulated transcription of targeted genes and other biological events2000
NF-AT polynucleotides2000
Regulated transcription of targeted genes and other biological events2000